NASDAQ:NVAX

Novavax Stock Predictions

Healthcare > Biotechnology

Buy NVAX

*Your capital is at risk

$10.20

-0.0100 (-0.0979%)

At Close: Jun 03, 2026

Currently predicting for Thu, 4 Jun 2026

NVAX Prediction Chart

NVAX Predictions History

Latest community submissions for NVAX.

Predictor	Target Session	Target Price	Result	Direction	Accuracy	Score
JS Pro	Feb 3, 2020	$7.84 +15.12%	$6.81	X	84.88%	0
Nators Amateur	Jan 28, 2020	$9.06 +26.36%	$7.17	X	73.64%	0
Nators Amateur	Jan 24, 2020	$7.79 -0.13%	$7.80	X	99.87%	6
Nators Amateur	Jan 22, 2020	$9.10 +28.35%	$7.09	X	71.65%	1
JS Pro	Jan 21, 2020	Bearish	$9.82	X	—	0
Nators Amateur	Jan 21, 2020	$6.45 -34.32%	$9.82	X	65.68%	1
ShinnJoseph128947	Dec 2, 2019	Bearish	$5.22	X	—	0
NameNotImportant Pro	May 6, 2019	$0.547 -94.05%	$9.23	V	5.93%	0
PumpTheseNumbers Pro	May 2, 2019	$0.576 -94.57%	$0.527	X	90.72%	0
AM	May 1, 2019	$0.500 -95.10%	$0.515	V	97.16%	0

Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for NVAX with a full price path, not just a one-day call.

Price path
Approved predictor
3-month horizon

Start Forecast Request View My Forecast Requests

Featured Predictors

GPT 5.4 Reply target 48h

Select

Gemini 3.5 Reply target 48h

Select

Opus 4.7 Reply target 48h

Select

ABOUT NOVAVAX INC

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical tria...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
LITE $905.00	3.65%	Jun 01
RUN $12.83	15.74%	May 06
GLBE $31.61	0.569%	May 05
SAP $172.39	4.80%	May 05
ADBE $243.57	5.20%	Apr 29

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by